The antibody-based drug was developed by specialists from the medical institutions of University College London and the Anglo-Swedish pharmaceutical company AstraZeneca. The drug is expected to provide immediate immunity against infection and protect against COVID-19 for 6 to 12 months.
“It would be a great addition to the arsenal of weapons being developed to combat this terrible virus,” said study leader Dr. Catherine Hoolihan.
If approved, the drug will be available in March or April. It is supposed to be provided as emergency care for hospital patients and nursing home residents.